Healthcare
Live Price
Offline$132.02
-1.15% today
1Y Change
+2.49%
Window
Jun 23, 2025 → Jun 1, 2026
Coverage: 236 bars · Jun 23, 2025 → Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Repligen Corporation (RGEN) is a Healthcare stock with a market cap of $6.61B and listed on NASDAQ. The stock last traded around $132.02 and up 2.5% across the available one-year price window (Jun 23, 2025 → Jun 1, 2026). Baseline metrics include revenue growth of +16.4%, EPS growth of +289.1%, a dividend yield of 0.0%. What stands out right now is revenue +16.4%, EPS +289.1%, free cash flow -34.1% with operating margin 7.6% and ROIC 1.5%. Valuation already assumes a fairly strong business story at P/E 135.5 and price/sales 9.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RGEN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGEN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RGEN Max Drawdown
-40.28%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RGEN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$670.5M
-16.3% YoY
FY Net Income
$128.3M
-31.0% YoY
Free Cash Flow
$47.7M
+23.2% YoY
Revenue Growth
+16.4%
EPS Growth
+289.1%
Gross Margin
50.9%
Net Margin
6.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 738M | 634M | 632M | 802M | 671M |
| Gross Profit | 348M | 275M | 278M | 456M | 391M |
| Operating Income | 60M | -35M | 48M | 225M | 167M |
| EBITDA | 164M | 80M | 145M | 277M | 203M |
| Net Income | 49M | -26M | 36M | 186M | 128M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 566M | 757M | 751M | 523M | 604M |
| Total Assets | 2.9B | 2.8B | 2.8B | 2.5B | 2.4B |
| Total Liabilities | 844M | 857M | 866M | 621M | 608M |
| Shareholder Equity | 2.1B | 2.0B | 2.0B | 1.9B | 1.8B |
| Total Debt | 690M | 686M | 712M | 423M | 366M |
| Net Debt | 124M | -71M | -40M | -100M | -238M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
119M
-30.8% YoY
Capital Expenditures
71M
+46.5% YoY
Free Cash Flow
48M
+23.2% YoY
Key ratios
Gross Margin
50.9%
Operating Margin
7.6%
Net Margin
6.6%
ROE
2.4%
Debt / Equity
0.33x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.